Genomic Testing Market Set to Double by 2031, Reaching USD 30.08 Billion at a CAGR of 9.54 percent Astute Analytica
| ALT Stock | USD 8.25 0.07 0.86% |
Slightly above 51% of Altimmune's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Altimmune suggests that some traders are interested. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
Altimmune |
Genomic Testing Market Set to Double by 2031, Reaching USD 30.08 Billion at a CAGR of 9.54 percent Astute Analytica
Read at kalkinemedia.com
 |
Altimmune Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Altimmune Fundamental Analysis
We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Altimmune is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Altimmune Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.
Peers
Altimmune Related Equities
| CGTX | Cognition Therapeutics | 8.62 | ||||
| INZY | Inozyme Pharma | 6.41 | ||||
| ATHA | Athira Pharma | 5.45 | ||||
| MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
| AKRO | Akero Therapeutics | 3.31 | ||||
| CABA | Cabaletta Bio | 3.03 | ||||
| ARDX | Ardelyx | 2.77 | ||||
| DAWN | Day One | 2.65 | ||||
| SAVA | Cassava Sciences | 2.62 | ||||
| AVXL | Anavex Life | 1.89 | ||||
| VKTX | Viking Therapeutics | 1.83 | ||||
| ACAD | ACADIA Pharmaceuticals | 0.84 | ||||
| XFOR | X4 Pharmaceuticals | 0.16 | ||||
| HEPA | Hepion Pharmaceuticals | 0 | ||||
| INMB | INmune Bio | 0.45 | ||||
| FBIO | Fortress Biotech | 1.15 | ||||
| ZURA | Zura Bio | 2.56 | ||||
| TERN | Terns Pharmaceuticals | 3.14 | ||||
| HOOK | Hookipa Pharma | 5.61 | ||||
| VSTM | Verastem | 5.63 | ||||
| BIVI | Biovie | 8.65 | ||||
| RVPH | Reviva Pharmaceuticals | 10.67 |
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.